

ForPatients

by Roche

Schizophrenia

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02953639 BP39207

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02953639 BP39207
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years & <= 50 Years

Healthy Volunteers
No
